

Marieke J Van Son

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3298958/publications.pdf>

Version: 2024-02-01

13
papers

205
citations

1307594

7
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

262
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	1.9	41
2	Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the <scp>Multi-centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (MIMIC)</scp> study. <i>BJU International</i> , 2019, 124, 504-513.	2.5	32
3	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	3.9	28
4	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1045-1053.	0.8	26
5	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. <i>Cancers</i> , 2018, 10, 480.	3.7	24
6	A Comparison of Prostate Cancer Detection between Visual Estimation (Cognitive Registration) and Image Fusion (Software Registration) Targeted Transperineal Prostate Biopsy. <i>Journal of Urology</i> , 2021, 205, 1075-1081.	0.4	23
7	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1120-1128.	3.9	10
8	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. <i>Cancers</i> , 2022, 14, 781.	3.7	8
9	Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 1-7.	1.7	5
10	Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 7-14.	1.7	4
11	Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 186-192.	3.9	2
12	Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspective. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 81-87.	1.7	1
13	Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer. <i>Cureus</i> , 2018, 10, e2429.	0.5	1